Welcome to our dedicated page for RHYTHM PHARMACEUTICALS SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on RHYTHM PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into RHYTHM PHARMACEUTICALS's regulatory disclosures and financial reporting.
Rhythm Pharmaceuticals EVP Jennifer Kayden Lee reported multiple transactions in company equity on August 13, 2026. She exercised stock options covering 56,601 shares of common stock at exercise prices of $24.29 and $6.80 per share, receiving the corresponding common shares. She then sold 75,834 shares of common stock at a price of $117.3818 per share. All exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2026.
Rhythm Pharmaceuticals EVP Yann Mazabraud exercised stock options to acquire 46,625 shares of common stock at an exercise price of $6.80 per share and reported continuing to hold 35,875 stock options after the exercise. On the same date, he sold an aggregate of 57,000 shares of common stock in multiple open-market transactions at weighted-average prices ranging from approximately $111.58 to $117.60 per share. The exercise and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2026, and the options exercised were part of a grant made on February 9, 2022 that vests in substantially equal quarterly installments.
A holder of RYTM common stock filed a notice to sell up to 5,079 shares through Morgan Stanley Smith Barney LLC on or after 08/13/2026 on NASDAQ. The shares relate to an exercise of stock options from 2024 and restricted stock units dated 02/01/2025, with an aggregate market value of $597,290.40.
RYTM filed a notice of proposed sale of common stock, to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ. The securities information section lists 75,834 shares, including 56,601 shares tied to an Exercise of Stock Options dated August 13, 2026, and 19,233 shares related to Restricted Stock Units dated February 11, 2024.
Rhythm Pharmaceuticals has a planned sale of 57,000 shares of its common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on August 12, 2026. The shares have an aggregate market value of $6,432,165.00 and are listed on NASDAQ. The sale includes 46,625 shares issuable from the exercise of stock options dated August 12, 2026, and 10,375 shares from restricted stock units dated April 14, 2024.
Rhythm Pharmaceuticals insider Pamela Cramer filed a Form 144 indicating planned sales of company common stock through Morgan Stanley Smith Barney LLC. The filing lists 10b5-1 plan sales and includes shares issuable from stock option exercises and restricted stock units, as well as a prior sale of 3,520 shares for $411,452.80 on August 10, 2026.
Rhythm Pharmaceuticals, Inc. reported total revenues of $71.3 million for the quarter ended June 30 2026, all from IMCIVREE product sales, up from $48.5 million a year earlier. U.S. net product revenue was $51.0 million and international revenue was $20.3 million.
The company recorded a quarterly net loss of $49.3 million and a basic and diluted net loss per share of $0.73, with an accumulated deficit of $1.46 billion. As of June 30 2026, cash, cash equivalents and short‑term investments totaled $330.9 million, against a deferred royalty obligation of $106.1 million and Series A convertible preferred stock carrying value of $114.3 million. Management believes existing cash resources will be sufficient to fund operations for at least the next 24 months while it continues commercial expansion and development of its MC4R‑pathway pipeline.
Rhythm Pharmaceuticals, Inc. reported second‑quarter 2026 results highlighted by uptake of IMCIVREE for acquired hypothalamic obesity. Net product revenue from global IMCIVREE sales was $71.3 million, a 19% sequential increase, with U.S. revenue of $51.0 million (72% of the total) and ex‑U.S. revenue of $20.3 million, which included a $3.8 million French Contribution M charge. Net loss attributable to common stockholders was $(50.4) million, or $(0.73) per share. Cash, cash equivalents and short‑term investments were $330.9 million as of June 30, 2026, which the company expects will fund operations for at least 24 months.
Since FDA approval in March 2026, the acquired HO launch generated more than 400 patient start forms from approximately 300 prescribers and increased reimbursed patients by greater than 20% quarter over quarter. Preliminary Phase 2 data for weekly injectable RM‑718 in acquired HO showed a −11.6% mean BMI reduction at 16 weeks (n=7), comparable to prior results with setmelanotide and bivamelagon, with only mild, localized hyperpigmentation noted. Rhythm reiterated 2026 Non‑GAAP operating expense guidance of $363–$397 million and outlined milestones including a Japan IMCIVREE HO launch decision by year‑end 2026, European launches beginning in 2027, and initiation of a pivotal Phase 3 bivamelagon trial.